CoChat

Rapastinel - an investigational NMDA-R modulator for major depressive disorder: evidence to date

Ragguett, Renee-Marie, Rong, Carola, Kratiuk, Kevin, McIntyre, Roger S. · 2019 · Expert Opinion on Investigational Drugs

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

Introduction Major depressive disorder (MDD) is a debilitating disorder with increasing prevalence globally. Despite the development of novel treatments for MDD, many patients present with treatment resistant depression (TRD), identified by treatment non-response following one or more adequate trials of an antidepressant. Rapastinel may prove to be a viable treatment for TRD; it has the potential to produce a rapid antidepressant response without serious adverse events and improve functional symptoms. Areas covered: We review the efficacy of rapastinel via completed and on-going clinical trials. The online databases Pubmed, clinicaltrials.gov and clinicaltrialsregister.eu were searched for rapastinel (GLYX-13) treatment in subjects with MDD. Nine clinical trials were identified. Expert opinion: Rapastinel is a novel and potentially transformative treatment for individuals with TRD. There is a limited number of clinical studies so far, but this compound has the potential to provide rapid, reliable and robust antidepressant effects without psychotomimetic and other unwanted side effects. Alternative formulations such as the oral formulation, provide the opportunity for rapastinel to be administered less frequently, i.e. once weekly. Furthermore, the beneficial effects on measures of cognition and suicidality so far, represent a tremendous advantage.

Overview

Integrity signals

Registry

Crossref · 10.1080/13543784.2019.1559295

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 31 references

Research works printed but not linked: 2

  1. Moret C, 2005, Neuropsychiatr Dis Treat, 1, 301
  2. Thase ME, 1997, J Clin Psychiatry, 58, 23

Cited by

See all 30

Metadata

Authors
Ragguett, R.-M., Rong, C., Kratiuk, K., & McIntyre, R. S.
Affiliations
  • University Health Network (CA)
  • Poznan University of Medical Sciences (PL)
Corresponding author
McIntyre, Roger S.
Venue
Expert Opinion on Investigational Drugs
Published
2018-12-26
Volume
28
Issue
2
Pages
113-119
ISSN
  • 1354-3784 (ISSN-L)
  • 1744-7658
OpenAlex
W2905977615
Cited by
30
References
31
Citations by year
2026: 2 · 2025: 4 · 2024: 3 · 2023: 1 · 2022: 5 · 2021: 4 · 2020: 5 · 2019: 6
FWCI
2.42
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Investigational Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Keywords
major depressive disorder, treatment-resistant depression, NMDA receptor modulators, antidepressant efficacy, rapid antidepressant response, suicidality, cognition, clinical trials
MeSH terms
Administration, Oral, Animals, Antidepressive Agents, Major Depressive Disorder, Drug Administration Schedule, Humans, Oligopeptides, Time Factors, Receptors, N-Methyl-D-Aspartate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rapastinel - an investigational NMDA-R modulator for major depressive disorder: evidence to date. https://app.cochat.ai/papers/10.1080/13543784.2019.1559295
The paper
Ragguett, R.-M., Rong, C., Kratiuk, K., & McIntyre, R. S. (2019). Rapastinel - an investigational NMDA-R modulator for major depressive disorder: evidence to date. Expert Opinion on Investigational Drugs. https://doi.org/10.1080/13543784.2019.1559295

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.